Alex Chehrazi-Raffle

Trials

Studies that name Alex Chehrazi-Raffle as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 18:22 UTC. Open this list on ClinicalTrials.gov

• Ph1
  NCT07219147 · 177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer

  City of Hope Medical Center · recruiting · Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 · principal investigator
• Ph1
  NCT07218913 · Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors

  City of Hope Medical Center · recruiting · Hearing Loss, Metastatic Malignant Germ Cell Tumor, Metastatic Malignant Nongerminomatous Germ Cell Tumor · principal investigator
• Ph1
  NCT06399419 · CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer

  Osel, Inc. · unknown · Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-11 18:22 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• Leadership, Planning and Evaluation
  P30CA033572 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI JOHN D. CARPTEN · fiscal years 2004 to 2026
  Named on NCT07219147, NCT07218913, NCT06399419